> Detailanzeige

Lemech, Charlotte R.; Ensell, Leah; Paterson, Jennifer C.; Eminowicz, Gemma; Lowe, Helen; Arora, Rupali; Arkenau, Hendrik-Tobias; Widschwendter, Martin; MacDonald, Nicola; Olaitan, Adeola; Mould, Tim; Meyer, Tim; Hartley, John; Mitra, Anita; Ledermann, Jonathan A.; McCormack, Mary; Kristeleit, Rebecca S.

Enumeration and Molecular Characterisation of Circulating Tumour Cells in Endometrial Cancer

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Enumeration and Molecular Characterisation of Circulating Tumour Cells in Endometrial Cancer
  • Beteiligte: Lemech, Charlotte R.; Ensell, Leah; Paterson, Jennifer C.; Eminowicz, Gemma; Lowe, Helen; Arora, Rupali; Arkenau, Hendrik-Tobias; Widschwendter, Martin; MacDonald, Nicola; Olaitan, Adeola; Mould, Tim; Meyer, Tim; Hartley, John; Mitra, Anita; Ledermann, Jonathan A.; McCormack, Mary; Kristeleit, Rebecca S.
  • Erschienen: S. Karger AG, 2016
  • Erschienen in: Oncology, 91 (2016) 1, Seite 48-54
  • Sprache: Englisch
  • DOI: 10.1159/000445999
  • ISSN: 0030-2414; 1423-0232
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <b><i>Background:</i></b> This is a feasibility study to determine whether circulating tumour cells (CTCs) are detectable and suitable for molecular profiling in advanced endometrial cancer (aEC). <b><i>Method:</i></b> Between October 2012 and February 2014, 30 patients with aEC had baseline and up to 3 follow-up samples. CTCs and stathmin expression were evaluated using the CellSearch platform. Epithelial cell adhesion molecule (EpCAM) and stathmin immunohistochemistry were performed on FFPE tumour tissue. <b><i>Results:</i></b> Eighteen from 30 (60%) patients had detectable CTCs during study [1 CTC (n = 7), 2 (n = 4), 3 (n = 1), 4 (n = 2), 7 (n = 1), 8 (n = 1), 22 (n = 1), 172 (n = 1) in 7.5 ml blood]. Ten from 18 patients had between 50 and 100% of detectable CTCs that were stathmin positive. More CTC-positive than CTC-negative patients had non-endometrioid versus endometrioid histology, tumour size ≥5 versus <5 cm, higher-stage disease and worse survival [hazard ratio 3.3, p > 0.05, 95% confidence interval 0.7-16.2]. Twenty-one tumour blocks were tested for EpCAM and stathmin immunohistochemistry (IHC). Stathmin tumour immunostaining scores (TIS) on IHC were higher in CTC-positive patients. <b><i>Conclusion:</i></b> CTC enumeration and molecular profiling with stathmin on the CellSearch platform is feasible in aEC. Stathmin TIS on IHC, a known prognostic marker in EC, was associated with CTC positivity.